NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a medical technology company focused on surgical solutions for neurological disorders, announced a planned chief financial officer succession. Ron McClurg will retire as CFO effective June 30, 2026, and will remain as a Senior Advisor through December 31, 2026, to ensure a smooth transition. Chris Volker, currently NeuroOne's Chief Operating Officer, will assume the permanent CFO role, while newly appointed Chief Business Officer David Wambeke will take over many of Volker's previous responsibilities.
Volker brings over 25 years of operational and financial leadership experience, particularly in the medical device industry. He holds the Chartered Financial Analyst (CFA) designation and earned his MBA from The Wharton School of the University of Pennsylvania. His background includes senior roles at Abbott, Cardiovascular Systems, Inc. (CSI), and St. Jude Medical. At CSI, he served as Vice President & General Manager of International, overseeing international profit and loss and commercial expansion. Earlier in his career, he worked in healthcare and technology investment banking at Dain Rauscher, developing expertise in financial analysis, mergers and acquisitions, and strategic planning.
CEO Dave Rosa expressed gratitude for McClurg's five years of service, noting his leadership and stewardship. Rosa stated, "Ron's retirement marks the culmination of a long and successful career, and we are grateful for his leadership, stewardship, and commitment to NeuroOne." Rosa also expressed confidence in Volker, saying, "Chris brings deep leadership experience across medtech, finance, strategy and commercial operations, and I believe he is the right person to step into this role as we continue advancing NeuroOne's technologies and growth strategy."
McClurg commented, "It has been a privilege to serve as NeuroOne's Chief Financial Officer for over five years and to work alongside such a talented team. I remain fully committed to supporting NeuroOne through this transition period." Volker added, "NeuroOne has built strong momentum, both in advancing our product pipeline and commercially, and I look forward to working closely with the team, as well as with Ron during this transition, to support the Company's strategic, operational, and financial objectives."
NeuroOne markets a minimally invasive electrode technology platform with four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System, and OneRF® Trigeminal Nerve Ablation System. The company is also engaged in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs. For more information, visit nmtc1.com.
The succession plan is part of NeuroOne's strategy to strengthen its leadership as it continues to advance its technologies and commercial growth. The transition is expected to be orderly, with McClurg providing advisory support through the end of 2026.
